Navigation Links
Covance Central Laboratories and NeoGenomics Enter into Exclusive Alliance to Provide Comprehensive Anatomic Pathology, Histology and Specialty Laboratory Testing Services for Clinical Trials
Date:11/18/2013

PRINCETON, N.J. and FT. MYERS, Fla., Nov. 18, 2013 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD), one of the world's largest and most comprehensive drug development services companies, and NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology-focused genetics testing services, today announced a strategic collaboration to jointly provide anatomic pathology and specialty laboratory testing services for global clinical trials. 

Through the alliance, Covance's clients will gain access to fully integrated anatomic pathology and histology (APH) services, including immunohistochemistry (IHC), fluorescence in-situ hybridization (FISH), and molecular testing.  Covance will establish a laboratory at NeoGenomics' Fort Myers, Fla. facility and, together with NeoGenomics, will provide a full range of APH, tissue-based biomarkers and other specialty testing services.  The companies will then expand joint capabilities globally at Covance's central laboratory locations in Shanghai, China; Geneva, Switzerland; and Singapore. 

As part of the alliance, Covance will have access to NeoGenomics' extensive medical and scientific networks, which includes more than 500 pathologists.  NeoGenomics gains access to Covance's broad market reach, established client relationships, and extensive clinical trials experience.  The alliance will provide seamless global testing services supporting oncology and companion diagnostics strategies for biopharmaceutical firms around the world. 

"The collaboration with NeoGenomics will offer our clients fully integrated anatomic pathology services from sample preparation, staining and imaging, to pathology interpretation by leading pathologists, in an end-to-end manner," said Paul Kirchgraber, MD, Vice President of Laboratory Operations & Medical Affairs, Covance Central Laboratory Services.  "Providing these integrated services through the Covance laboratory co-located within NeoGenomics results in improved turnaround times critical to oncology clinical trials."  

Douglas VanOort, NeoGenomics Chairman and CEO, stated, "Our oncology-focused genetic and molecular testing services are a perfect complement to Covance's extensive laboratory services and will allow NeoGenomics to rapidly grow its clinical trials business with a world-class partner.  We also look forward to the exciting opportunities that this collaboration will open up in the field of companion diagnostics."   

About Covance Inc.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $2.2 billion and more than 12,000 employees located in over 60 countries.  Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

About NeoGenomics, Inc.

NeoGenomics is a high-complexity CLIA–certified clinical laboratory that specializes in cancer-focused genetic and molecular testing services.  The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing.  NeoGenomics services the needs of pathologists, oncologists, other clinicians and hospitals throughout the United States. Information on NeoGenomics' products and services, press releases, and SEC filings can be obtained through its website at www.neogenomics.com.   

Forward-Looking Statements

Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  All such forward-looking statements are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.  These risks and uncertainties include, without limitation, factors described in each of Covance's and NeoGenomics filings with the Securities and Exchange Commission including their Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.  Neither Covance nor NeoGenomics undertakes any duty to update any forward-looking statement to conform the statement to actual results or changes in either company's expectations.

 

 

 


'/>"/>
SOURCE Covance Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Covance To Present At The Credit Suisse Healthcare Conference
2. Covance Reports Third Quarter Net Revenue Of $607 Million, Pro Forma EPS Of $0.83 And Adjusted Net Orders Of $732 Million
3. Covance Launches Managed Markets Services
4. Financial Results, Earnings Schedules, Quarterly Dividends, and Top Rankings - Research Report on Quest Diagnostics, PerkinElmer, PAREXEL, Covance, and ICON
5. Covance Inc. Invites You to Join the Webcast of Its Second Quarter 2013 Financial Results Conference Call
6. Covance Reports Second Quarter Net Revenue of $592 Million, Pro Forma EPS of $0.78 and Record Adjusted Net Orders of $776 Million
7. Covance Central Laboratory Services Again Ranks #1 in Global Investigator Satisfaction Survey
8. Covance To Present At The Goldman Sachs 34th Annual Global Healthcare Conference
9. Covance Reports First Quarter Net Revenue Growth Of 9.3% To $580 Million, Pro Forma EPS Of $0.75 And Adjusted Net Orders Of $716 Million
10. Covance Expands Singapore Central Laboratory by 50 Percent to Meet Clients Increased Asia Pacific Focus
11. Covance Inc. Invites You to Join the Webcast of Its First Quarter 2013 Financial Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , May 26, 2016 Since ... matured into an essential life science tool for conducting ... applications. BCC Research reveals in its new report that ... growth phase, one powered by a range of new ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
(Date:5/25/2016)... PARIS , May 25,2016 ... with the near-infrared Cellvizio platform for urological and ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... important regulatory milestone in the US with the ... Food and Drug Administration (FDA). This new FDA ...
(Date:5/25/2016)... 25, 2016 According to a ... (3D, 2D, 4D), by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), ... (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast to 2021", ... Animation Market for the forecast period of 2016 to ... Million by 2021 from USD 117.3 Million in 2016, ...
Breaking Medicine Technology:
(Date:5/26/2016)... NJ (PRWEB) , ... May 26, 2016 , ... ... recognized as an NJ Top Doc! Along with his wonderful accolades and stellar ... in podiatry. Congratulations, Dr. Batelli! , Dr. Eugene Batelli is a highly ...
(Date:5/26/2016)... ... May 26, 2016 , ... Power Systems, ... the first PowerWave Instructor Certification Course in Stoughton, Massachusetts. The course was led ... professional through the 8 hour interactive course to qualify participants as certified PowerWave ...
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie , the manufacturer ... treatment was more than humbled by customer demand over the Mother’s Day Weekend promotion. ... sale. Now that Bunion Bootie has completely replenished its inventory levels, it hopes to ...
(Date:5/26/2016)... ... May 26, 2016 , ... OncLive® , a ... Cancer Institute-designated University of Virginia (UVA) Cancer Center to its quickly ... and marketing teams will publicize and promote public awareness of UVA Cancer Center’s ...
(Date:5/26/2016)... ... May 26, 2016 , ... On May 23rd during the National Eye ... and international water advocate, was honored by Ashram, Inc. as the world’s foremost water ... knelt on the banks of the Nile to fill their red clay pots with ...
Breaking Medicine News(10 mins):